Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose

Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine

“…Nevertheless, moderate-to-severe AEs were markedly more common in our cohort compared to the COV-BOOST trial that used the same AE grading system following third/booster doses of BNT162b2/Pfizer (AEs<5%;n=96) [16] . Our finding of progressive reductions in AEs across successive doses contrasts with both our prior work (showing AEs increased between doses one and two [10] ) and a recent Israeli stud showing the opposite effect [17] . This might have occurred because either the present work involved a new sample of HCWs (hence individual differences) or HCWs becoming more accustomed to vaccine-associated AEs over time.…”

Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study

“… 17 In the context of the primary COVID-19 vaccination series (first and second dose), studies using wearables found more apparent changes in heart measures following vaccination with the second dose compared with the first dose on the second day following vaccination, in individuals vaccinated with the Moderna vaccine versus the Pfizer–BioNTech vaccine, and among vaccinated individuals not previously infected with COVID-19 versus those who were vaccinated and infected. 11 , 12 , 13 All of these heart measures were previously reported to correlate with subjective symptoms after the COVID-19 vaccine. 18 , 19 Nevertheless, the value of smartwatch measurements (eg, heart rate) for the identification of vaccine-associated adverse events has yet to be established.…”

“…Although severe events after vaccination will likely lead to a medical consultation, which would be noted in the patient's medical records, milder reactions are generally underreported. One promising direction to close this gap and provide a more comprehensive assessment of the safety of vaccines is to conduct extensive, continuous, and detailed monitoring and surveillance of physiological changes in vaccinated individuals 11 , 12 , 13 , 14 Moreover, several studies have shown the excellent ability of wearable sensors from smartwatches to detect unnoticeable medical conditions. For example, as part of the Apple heart study, 15 the ability to continuously monitor smartwatch sensors to detect atrial fibrillation based on an irregular heart pulse was shown.…”

“…In this study, we aimed to evaluate the safety profile of the second BNT162b2 mRNA COVID-19 booster vaccine. To do so, we examined the short-term effects (ie, the effects lasting up to 42 days) of the second BNT162b2 mRNA COVID-19 booster vaccine and compared it with the first booster by analysing data from both a prospective cohort of 4698 participants as part of the PerMed observational prospective study 11 , 12 , 14 and a retrospective cohort of 250 000 random members of Maccabi Healthcare Services, the second-largest health-care provider in Israel.…”

Strong Humoral but Not Cellular Immune Responses against SARS-CoV-2 in Individuals with Oncohematological Disease Who Were Treated with Rituximab before Receiving a Vaccine Booster

“…The vaccine efficacy against severe COVID-19 remains high (≥80%) for up to 6 months after vaccination; however, from this point, a progressive decline has been observed [ 20 , 21 ] that is even lower in immunocompromised individuals in comparison with healthy controls (79–90.2% vs. 84–100%, respectively) [ 22 ]. Therefore, a booster or third dose of COVID-19 vaccine was approved to induce additional protection against SARS-CoV-2 infection [ 23 ] without causing an increased risk of adverse events or systemic reactions [ 24 ]. Consequently, the use of both mRNA-based vaccines for booster vaccinations in persons aged 18 years and over and to people with severely weakened immune systems was authorized for COMIRNATY at a full dose and for Spikevax at half the dose, at least 28 days after their second dose [ 25 ].…”